Humana (HUM) › Analysis

Humana (HUM) stock analysis, November 18, 2026: Pullback oversold, bullish outlook

Published November 18, 2026 · HUM chart, levels and live analysis

Humana Inc. fell more than 5% on November 18 after regulatory headlines and a broader sector sell‑off, leaving the price at $408.61. The move pushed the stock into an oversold pullback inside a multi‑week uptrend that remains intact, and the balance of evidence still leans bullish for the next two to six weeks. A daily close above the 50‑day SMA at $410.85 on volume above the 20‑day average would confirm the upside bias, while a weekly close below $405.26 would invalidate it.

Why it matters

The immediate catalyst was renewed scrutiny of Medicare Advantage rules, highlighted in a Nasdaq story that noted both UnitedHealth and Humana slipped 4%–5% on the news (NASDAQ). The regulatory pressure is a sector‑wide factor, not a company‑specific earnings surprise, and the market priced in the risk quickly, as evidenced by the 5‑day stock decline of 8.45% versus a 3.50% drop in the XLV health‑care ETF. The stock’s under‑performance relative to its sector (‑4.9% excess) shows the move was driven more by the headline than by fundamentals.

Prior to the dip, Humana had posted a stronger‑than‑expected third‑quarter earnings report, prompting an upgrade to Outperform and a price‑target lift to $563 from $415 (Investing.com). That positive earnings narrative was largely intact on November 18, as the 5‑day price action still reflects a pullback rather than a reversal. The market’s reaction therefore appears to be a short‑term risk premium for regulatory uncertainty.

Analyst consensus remains a “Buy” with a mean target of $504, implying a 19% discount to the current price (NASDAQ). The spread between the low target ($280) and the high ($602) underscores divergent views, but the median target still sits well above the $410.85 breakout level, supporting the bullish bias.

Both sides of the debate acknowledge the regulatory headwinds. A Morningstar piece on November 12 highlighted a broad upgrade wave for health‑care stocks, including Humana, citing fair‑value lifts of 48% for the sector (Morningstar). Conversely, a Yahoo! Finance column on November 1 quoted Mark Cuban urging investors to avoid large insurers, framing the sector as a cost‑driver for the economy (Yahoo! Finance). The weight of evidence, however, remains on the upside side because the regulatory news has already been priced into the decline, and the longer‑term trend stays intact.

What the evidence says

On the long‑term horizon the thesis is unchanged: Humana trades above its 40‑week average, the 50‑day SMA sits at $410.85, and the 52‑week high of $461.25 still defines the swing‑zone target. The recent pullback has not broken the structural support at $400, nor has it breached the trend‑ending level of $353.38, so the long‑term uptrend remains intact.

For the next two to six weeks the balance of evidence leans positive with high conviction. The assessment notes a pullback that has entered oversold territory, a 50‑day SMA breakout condition, and a reward‑to‑risk profile that meets a 3‑to‑1 ratio for the primary target at $461.25. The strongest counter‑argument is the 5‑day under‑performance of the stock relative to its sector (‑4.9% excess) and the volume deficit of 57.6% versus the 20‑day average, suggesting limited buying pressure. Those factors keep conviction from being absolute, but they do not overturn the bullish reading.

Levels that matter

The price structure holds above the round $400 level; a break below would be the first crack and would signal weakening of the weekly trend. The trend would be considered ended if the price fell below the swing‑zone support at $353.38 on a weekly close, as defined in the picture‑change rule.

The breakout math calls for a daily close above the 50‑day SMA at $410.85 on volume above the 20‑day average. The stop is set at $394.75, derived from $400 minus a quarter of the 14‑day ATR ($21.02). The first target at $414.29 (swing‑zone) offers a modest 0.2‑to‑1 reward‑to‑risk, while the secondary target at $461.25 (52‑week high) provides a 3.1‑to‑1 ratio. Because the assessment meets the 3‑to‑1 criterion, the math supports a favorable risk profile.

What would change the picture

A weekly close below the swing‑zone support at $353.38 would invalidate the current bullish outlook, as it would indicate the weekly trend has ended. A non‑price factor that could also shift the narrative is a decisive regulatory outcome—such as the CMS “CRUSH” initiative being softened or withdrawn—removing the primary headwind that sparked the recent sell‑off.

What to watch

Get a message when the HUM picture changes — the agent team watches the levels and the news for you.Create a free account

More HUM analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.